NRP1 and neoplasm: In a preclinical xenograft NSCLC model, administration of a function-blocking anti-NRP1B antibody in order to block VEGF binding to NRP1, resulted in marginal tumor growth delay and additive effects to anti-VEGF therapy in reducing tumor growth.